SRP 1002
Alternative Names: ARO-MMP7; SRP-1002Latest Information Update: 23 Jun 2026
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antifibrotics; Small interfering RNA
- Mechanism of Action Matrix metalloproteinase 7 expression inhibitors; RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Idiopathic pulmonary fibrosis
Most Recent Events
- 23 Jun 2026 Arrowhead Pharmaceuticals completes a phase-I/II clinical trials in Idiopathic pulmonary fibrosis in USA, Denmark, Spain, Italy, South Korea, United Kingdom (Inhalation) (NCT05537025)
- 10 Feb 2025 Arrowhead Pharmaceuticals completes global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programme
- 27 Nov 2024 Arrowhead Pharmaceuticals enters into global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programme